INS and hypertensive disorder: In three studies within the Ingenix (now Optum) administrative claims database [33-35], patients treated with sitagliptin, another DPP-4 inhibitor, were more likely to have medical comorbidities (i.e., cardiovascular disease, chronic kidney disease, hypertension, lipid disorders, and neuropathy) and were more frequently prescribed cardiovascular medications and insulin.